Kala Pharmaceuticals to Report Third Quarter 2020 Financial Results and Host Conference Call
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) has announced it will report its third quarter 2020 financial results on November 5, 2020. The conference call will take place at 8:00 a.m. ET, where management will discuss financial results and business updates. Kala is noted for its AMPPLIFY® Drug Delivery Technology, which led to the recent approval of EYSUVIS™ for dry eye disease and the launch of INVELTYS® for post-operative inflammation. Investors can access the call via dial-in or the company's website.
- Approval of EYSUVIS™ for treating dry eye disease is a significant milestone.
- Launch of INVELTYS® for post-operative inflammation showcases product pipeline strength.
- None.
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report third quarter 2020 financial results on Thursday, November 5, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET.
The dial-in numbers to access the conference call are 866-300-4091 (domestic) or 703-736-7433 (international) using the conference ID 9199546. To access a live webcast and subsequent archived recording of the call, please visit the “Investors & Media” section on the Kala website at http://kalarx.com/.
About Kala Pharmaceuticals, Inc.
Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus penetrating particle Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in the October 2020 approval of EYSUVISTM (loteprednol etabonate ophthalmic suspension)
